Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 2Phase NA 1Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 13Lymphoid 12Other hematologic neoplasm 10CNS 6Gynecologic 2Genitourinary 2Sarcoma 1Other solid neoplasm 1NET 1Gastrointestinal 1Endocrine 1Dermatologic 1Breast 1

Conditions

Solid Tumor 31Advanced Solid Tumors 12Advanced Solid Tumor 8Solid Tumors 7Mesothelioma 5Retinoblastoma 3Ovarian Neoplasms 3Hematopoietic and Lymphoid System Neoplasm 3TCR-T Cells 2Solid Tumor Malignancies 2Metastatic Solid Tumors (Any Localization) 2Mesothelioma, Malignant 2Malignant Solid Tumor 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Malignant Solid Tumor 2Unspecified Adult Solid Tumor, Protocol Specific 1Unresectable or Metastatic Advanced Solid Tumors 1Stomach Neoplasms 1Solid Tumor, Adult 1Sleep Apnea, Obstructive 1Sarcoma 1Rhinitis, Allergic, Seasonal 1Rhabdomyosarcoma 1Refractory Solid Tumors 1Recurrence 1Rectal Neoplasms 1Pulmonary Fibrosis 1Pulmonary Embolism 1Pulmonary Disease, Chronic Obstructive 1

Interventions

Topotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Recurrence × Other solid neoplasm × Clear all
NCT06972602 2025-05-15

High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed

Eye & ENT Hospital of Fudan University

Phase EARLY_PHASE1 Recruiting
10 enrolled
Other solid neoplasm

Recurrence, Retinoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡